{"filings":[{"id":100778,"accession_number":"0001140361-26-004822","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Strata Skin Sciences to be delisted from Nasdaq on Feb 19 after failing equity requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company failed to meet Nasdaq's minimum $2.5M stockholders' equity; funding efforts unsuccessful.","Nasdaq suspension of trading effective Feb 19, 2026; company will not appeal.","Plans to file Form 25 to delist and Form 15 to terminate SEC registration and 'go dark'.","Expects cost savings from reduced reporting obligations, enabling focus on operations and cash burn.","Stockholders face increased illiquidity; may sell shares before suspension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117080,"accession_number":"0001140361-25-045846","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin posts investor presentation; no material financial updates revealed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation posted Dec 16, 2025 on corporate website (gcs-web.com).","Presentation titled 'Driving Value in Therapeutic and Aesthetic Dermatology'; no new financial data or guidance included.","No specific product, revenue, or strategic milestones disclosed in the limited exhibit available.","Filing under Regulation FD; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117079,"accession_number":"0001140361-25-045145","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Strata Skin Sciences annual meeting elects all five directors; incentive plan amendment approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Dr. Uri Geiger, Dr. Irit Yaniv, Christina Allgeier, Shmuel Rubinstein, Dr. Dolev Rafaeli.","Shareholders approved amendment to 2016 Omnibus Incentive Plan, increasing reserved shares by 520,000.","Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2025 approved.","Votes for directors ranged from 2.18M to 2.23M; broker non-votes of 1.01M on director and plan items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117078,"accession_number":"0001140361-25-041985","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences Q3 revenue $6.9M (-21% YoY); net loss narrows to $1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.9M (-21% YoY); net loss $1.6M (EPS -$0.36) vs $2.1M loss (EPS -$0.51) last year.","Global recurring revenue $5.5M (+3% YoY); equipment revenue $1.4M (-60%).","EBITDA slightly positive vs -$0.2M; cash $7.1M after $2.4M registered direct offering.","CMS recognized expanded CPT codes for XTRAC; COFEPRIS cleared TheraClearX in Mexico.","XTRAC install base 838 (-6); TheraClearX 161; avg gross billings per device $5,981 (+8.5%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":21404000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117077,"accession_number":"0001213900-25-099578","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Strata Skin Sciences files prospectus supplement for up to $11M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registers up to $11.0M in common stock for sale at-the-market under existing S-3 registration statement.","Prospectus supplement dated September 26, 2025 filed with SEC; Ladenburg Thalmann acts as sales agent.","No actual sales or pricing disclosed; shares offered from time to time under equity distribution agreement.","Opinion of Stevens & Lee, P.C. on legality of shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117076,"accession_number":"0001213900-25-098755","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Strata Skin Sciences gains Nasdaq extension to Feb. 16, 2026 for equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq accepted Strata's plan and extended the deadline to Feb. 16, 2026 to meet the $2.5M stockholders' equity requirement.","Company originally received a deficiency notice on Aug. 22, 2025 and submitted a compliance plan on Sept. 19, 2025.","Strata is evaluating options to regain compliance, but cautions there is no guarantee of success; non-compliance by the deadline could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133528,"accession_number":"0001140361-25-034000","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences closes $2.42M registered direct offering of 1.1M shares at $2.204","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 1,097,547 shares at $2.204 per share.","Gross proceeds of approximately $2.42 million; Ladenburg Thalmann acted as placement agent.","Net proceeds to be used for working capital and general corporate purposes.","Offering was made under effective shelf registration statement (File No. 333-283418).","Closing occurred on September 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133527,"accession_number":"0001213900-25-083709","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences prices $2.42M registered direct offering at $2.204/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.","Gross proceeds expected ~$2.42M; net proceeds for working capital and general corporate purposes.","Ladenburg Thalmann acting as sole placement agent with 7.0% cash fee plus up to $50,000 expense reimbursement.","Closing expected on or about September 4, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133526,"accession_number":"0001140361-25-032373","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Strata Skin Sciences receives Nasdaq deficiency notice for equity below $2.5M; must submit plan by October 3, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Strata on Aug 19, 2025 of non-compliance with minimum stockholders' equity requirement of $2.5M.","Company reported equity below requirement in Q2 10-Q and does not meet alternative compliance standards.","Company has until Oct 3, 2025 to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180-day extension.","Failure to regain compliance could lead to delisting; company is evaluating options.","Stock continues trading under SSKN on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133525,"accession_number":"0001140361-25-031629","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences posts investor presentation on its website on August 18, 2025","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Strata Skin Sciences (NASDAQ: SSKN) posted an investor presentation to its website on August 18, 2025.","The presentation is attached as Exhibit 99.1 to the current Form 8-K filed with the SEC.","The company's presentation is available at https://strataskinsciencesinc.gcs-web.com/.","The disclosure is furnished under Item 7.01 and not deemed filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133524,"accession_number":"0001140361-25-030853","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences Q2 revenue down 9% to $7.7M; net loss widens to $2.5M, EPS -$0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.7M (down 9% YoY); net loss $2.5M vs $0.1M loss in Q2 2024 (EPS -$0.60 vs -$0.03).","Gross profit $4.3M (56% of revenue) vs $5.0M in prior year.","Cash at June 30 $6.0M; nearly operating cash flow breakeven when adjusted for $1.3M NY tax payment and ~$340k legal costs.","CPT code expansion triples covered patient population; G-code application filed for accelerated 2026 reimbursement.","Removed 21 XTRAC devices, placed 19 (highest in six quarters); lawsuit against LaserOptek adds defendants."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":14475000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133523,"accession_number":"0001140361-25-029355","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata seeks CMS temporary codes for expanded XTRAC reimbursement; triples addressable market to 30M+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Working with CMS to secure temporary codes for expanded CPT codes for XTRAC, aiming for 2026 reimbursement instead of 2027.","Expanded coding triples addressable patient population to over 30M for inflammatory and autoimmune skin conditions.","Two new studies show excimer laser plus JAK inhibitors safe and effective for vitiligo, supporting XTRAC use.","Federal court adds LaserOptek Korea and C. Dalton as defendants in false advertising lawsuit; STRATA encouraged by ruling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150201,"accession_number":"0001140361-25-019786","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AMA expands CPT codes for SSKN's XTRAC laser; now covers vitiligo, atopic dermatitis, alopecia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMA CPT Editorial Panel revised codes 96920-96922 to include inflammatory/autoimmune skin diseases beyond psoriasis.","Expanded coverage unlocks up to 30M potential patients (vs. 10M psoriasis-only), including 3M vitiligo, 16.5M atopic dermatitis patients.","Expected to reduce systemic denials and prior authorizations; non-psoriasis treatments were ~30% of 2023 Medicare volume.","CEO Dr. Rafaeli calls it an 'inflection point' for XTRAC; company expects accelerated revenue growth and broader clinic adoption.","STRATA collaborated with leading dermatologists (Dr. Lebwohl, Dr. Grimes, Dr. Richard) on the CPT change application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150200,"accession_number":"0001140361-25-019005","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q1 2025 revenue $6.8M up 1%; net loss narrows to $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.8M (+1% YoY); gross margin expanded 790 bps to 53.5%.","Net loss $2.4M (EPS -$0.58) vs $3.4M loss (-$0.96) in Q1 2024.","Adjusted EBITDA improved to -$0.55M from -$1.3M; operating expenses fell 5% to $5.7M.","International revenue grew 8% YoY, now 36% of total; DTC drove 32% more psoriasis patients.","Cash at quarter-end $7.8M; operating cash flow improved to -$0.55M."],"consensus_eps_estimate":-0.5263,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":6812000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150199,"accession_number":"0001140361-25-015780","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Strata Skin Sciences replaces auditor: Marcum resigns, CBIZ engaged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 23, 2025; CBIZ CPAs P.C. engaged same day with Audit Committee approval.","No disagreements with Marcum on accounting principles or financial statement disclosure during FY2024/2023 or through resignation.","Prior material weakness in internal controls (lack of detailed management review) was reported; no other reportable events.","Marcum's audit reports for FY2024 and FY2023 were unqualified and not modified as to uncertainty or scope.","Marcum's resignation followed CBIZ's acquisition of Marcum's attest business on November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169210,"accession_number":"0001140361-25-010713","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Q4 rev +10% to $9.6M; net loss $4.5M; adj. EBITDA improves to $2.2M in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $9.6M, up 10% from $8.7M; net loss $4.5M (EPS -$1.18 vs -$1.09).","Full-year 2024 revenue $33.6M (flat); net loss $10.1M (EPS -$2.65).","Gross margin improved to 60.1% in Q4 (480 bps YoY); non-GAAP adj. EBITDA $2.2M vs $1.0M.","Domestic XTRAC units reduced to 864; avg rev per device up 6% to $5,906.","International Q4 sales $4.1M (+41% YoY); cash $8.6M at year end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169209,"accession_number":"0001140361-25-009587","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences highlights clinical study showing excimer laser superiority over excimer light","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Published study from Nippon Medical School shows excimer laser penetrates deeper into hair follicles and activates more melanocyte stem cells than excimer light.","Laser delivers 1,000 mJ/cm² in one second vs 20 seconds for excimer light, with less DNA damage and epidermal side effects.","Over 100 XTRAC excimer lasers placed in Japan since 2019, including 24 in 2024; global installed base exceeds 2,800 units.","CEO states study validates XTRAC's technological advantages for treating vitiligo, psoriasis, alopecia areata, and atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186249,"accession_number":"0001140361-24-048963","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences posts investor presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation posted to company website on December 11, 2024.","Presentation titled 'Driving Value in Dermatology' with tagline 'Matching Patients with Clinics'.","No specific financial results, guidance changes, or material events disclosed in filing.","Filing is for Regulation FD purposes; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186248,"accession_number":"0001140361-24-046508","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q3 rev $8.8M, first non-GAAP operating profit since 2018","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.8M (-1% YoY); recurring revenue $5.4M (+2% YoY); gross margin 60.3% (up from 56.0% YoY).","Non-GAAP operating profit $128K (excl. $1.8M NY tax accrual); first since 2018 refinancing.","Net loss narrowed to $0.3M ($0.08/sh) from $1.1M ($0.30/sh) in Q3 2023; cash $8.4M.","XTRAC domestic base 873 (down from 882 Q2); TheraClear X base 135 (up from 117 Q2).","Designated John Gillings (VP Finance) as principal financial & accounting officer; raised $2.1M in July equity offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":23986000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186247,"accession_number":"0001140361-24-045945","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences wins court order barring LaserOptek from false marketing of Pallas lasers","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Eastern PA issued order in STRATA's favor against LaserOptek, Monarch Laser Services, and Pinnacle Health Group.","Order enjoins LaserOptek and Pinnacle from marketing Pallas lasers as reimbursable under CPT codes 96920-96922.","Also bars any false/misleading statements about Pallas lasers or STRATA's lasers in U.S. sales and promotion.","Court order is a partial conclusion of STRATA's preliminary injunction motion; STRATA continues pursuing monetary and equitable relief.","CEO Dolev Rafaeli states defendants' behavior caused significant monetary and reputational damages to STRATA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186246,"accession_number":"0001140361-24-044583","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Strata Skin Sciences shareholders re-elect all five directors and ratify Marcum LLP as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Dr. Uri Geiger, Dr. Irit Yaniv, Christina Allgeier, Shmuel Rubinstein, Dr. Dolev Rafaeli.","Ratification of Marcum LLP as independent registered public accounting firm for FY 2024 approved with 3,166,313 votes for, 53,201 against.","No other business proposals were presented or approved beyond the stated agenda."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202875,"accession_number":"0001140361-24-038470","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences sues LaserOptek, MLS, Pinnacle for false advertising of Pallas lasers","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in U.S. District Court for Eastern District of Pennsylvania alleging unfair competition and false advertising under Lanham Act.","Claims defendants misrepresented that Pallas lasers qualify for CMS reimbursement codes reserved for excimer lasers like STRATA's XTRAC.","Also alleges false statements of technological and clinical equivalence without scientific evidence, causing harm to competition and patients.","Seeks injunctive relief, actual and treble damages, disgorgement of profits, and legal costs from LaserOptek, MLS, and Pinnacle.","Defendants include Korean manufacturer LaserOptek (KOSDAQ), its U.S. distributor Monarch Laser Services, and advisor Pinnacle Health Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202874,"accession_number":"0001140361-24-037322","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.","Revenue $8.4M (+2% YoY); global recurring revenue $5.3M (-2% YoY) due to deferred billings; equipment revenue $3.1M.","Gross margin 58.5% vs 52.3% YoY; operating expenses $5.4M (-14% YoY).","XTRAC domestic base down to 882 from 907 at March; TheraClear X base up to 117 from 104.","Raised $2.1M in July offering; received Japan approval for XTRAC Momentum 1.0; renewed China/Japan distributor pacts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":15189000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202873,"accession_number":"0001140361-24-033878","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Closes $2.1M Direct Offering with Insider Participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 665,136 shares at $3.16/share for gross proceeds of $2.1 million.","Insiders and existing shareholders participated in the registered direct offering.","CEO Dolev Rafaeli said insider participation shows conviction in strategic plan and path to profitability.","Proceeds will extend the company's cash runway to support turnaround and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202872,"accession_number":"0001140361-24-033358","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences announces clinical study showing TheraClear X reduces acne lesions by ≥50% after three treatments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Cosmetic and Laser Therapy (July 11, 2024) evaluated 7 female patients with mild-moderate acne.","All patients achieved ≥50% clearance of comedones, pustules, and inflammatory lesions after three treatments.","Side effects were mild and transient: erythema, bruising, superficial erosions, temporary pigmentation changes (48-72 hours).","TheraClear X is FDA-cleared as a noninvasive, in-office treatment for mild-to-moderate acne, combining vacuum and broadband light.","President and CEO Dr. Dolev Rafaeli cited photopneumatic therapy as a viable alternative for patients resistant to traditional treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202871,"accession_number":"0001140361-24-032885","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"STRATA pre-announces Q2 revenue $8.0M-$8.4M; XTRAC base down, TheraClear X up","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q2 2024 total revenue range: $8.0M - $8.4M.","Domestic XTRAC installed base fell from 907 (Q1) to 881 (Q2) per device realignment.","TheraClear X installed base grew from 104 (Q1) to 117 (Q2).","Cash, cash equivalents, and restricted cash totaled $6.8M at quarter end.","Full Q2 2024 results expected to be reported on August 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":15189000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219069,"accession_number":"0001140361-24-031327","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"STRATA Skin Sciences regains Nasdaq compliance, avoids delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on June 24, 2024 that it now satisfies continued listing requirements under Rule 5550(a)(2).","Company will continue to trade on Nasdaq under ticker SSKN.","No additional details on prior deficiency or remedial actions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219068,"accession_number":"0001140361-24-028814","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Strata Skin Sciences announces 1-for-10 reverse stock split effective June 6, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 1-for-10 approved by board on April 26, 2024, effective 11:59 p.m. June 6.","Post-split common stock begins trading on Nasdaq Capital Market on June 7, 2024, under same symbol SSKN.","New CUSIP number 86272A 305; no fractional shares issued, cash paid in lieu.","Stockholders' percentage interest unchanged; outstanding equity awards proportionally adjusted.","Stockholders pre-approved the reverse split range (1:5 to 1:25) at special meeting on October 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219067,"accession_number":"0001140361-24-026254","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q1 revenue $6.8M (-11% YoY); net loss widens to $3.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.8M vs $7.6M YoY; global recurring revenue $4.7M (-10% YoY).","Net loss $3.4M ($0.10 per share) vs $2.8M ($0.08) in Q1 2023.","Gross margin fell to 46% from 58% YoY; operating expenses cut 14% to $6.0M.","Domestic installed base: 907 XTRAC (down from 923 in Dec 2023); 104 TheraClear X (up from 92).","Amended credit agreement with MidCap Financial; renewed 3-year exclusive distributor deals in China and Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":6754000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219066,"accession_number":"0001140361-24-022571","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences announces 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-10 effective 11:59 p.m. ET June 6, 2024; trading begins June 7 under same symbol SSKN with new CUSIP 86272A 305.","Split aimed at meeting Nasdaq's $1.00 minimum bid price requirement for continued listing.","Shareholders approved a reverse split range (1-for-5 to 1-for-25) on October 26, 2023; announcement satisfies deadline to specify ratio by April 26, 2024.","No fractional shares issued; holders of fractional shares will receive cash based on pre-split closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238953,"accession_number":"0001140361-24-015650","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.","Full-year 2023 revenue $33.4M vs $36.2M; net loss $10.8M ($0.31 EPS) vs $5.6M loss.","Recorded $2.3M goodwill impairment in dermatology recurring procedures segment.","Installed XTRAC base 923 devices; launched TheraClear X acne system with 92 devices in operation.","Dr. Dolev Rafaeli appointed Vice-Chairman, President and CEO in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238952,"accession_number":"0001140361-24-009499","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences amends credit agreement, removes 2023 revenue covenants","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Amendment No. 4 removes minimum revenue requirements for 2023 and introduces future financial covenants.","Effective February 20, 2024; aligns credit terms with current and projected business operations.","Enhances liquidity and financial flexibility to support operational and capital needs.","CEO Dolev Rafaeli states amendment strengthens partnership with MidCap and enables strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238951,"accession_number":"0001140361-24-008801","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Strata Skin Sciences obtains waiver of Q4 2023 covenant breach, amends credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received limited waiver from MidCap for December 31, 2023 minimum net revenue covenant default.","New minimum net revenue thresholds for 2024: $29.0M (Q1), $29.25M (Q2), $29.5M (Q3), $30.0M (Q4).","Exit fee set at 4.0% of total principal borrowed; partial prepayment triggers proportionate fee.","Amended fee letter includes origination fees on future Credit Facility #3 draws at 0.50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238950,"accession_number":"0001140361-24-001339","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences presents TheraClear®X acne study at Maui Derm 2024","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Poster reports one treatment session using TheraClear®X with needle insert for cystic and papular acne.","Majority of lesions achieved ≥50% clearing by 1-2 weeks; average reduction score 3.5 (50-75% reduction).","Most frequent adverse event was mild hyperpigmentation; erythema, edema, flaking seen in ≤10% of lesions.","Conference takes place Jan 22-26, 2024 at Grand Wailea in Maui, Hawaii."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238949,"accession_number":"0001140361-24-000342","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences gets 180-day Nasdaq extension to June 24, 2024 for bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted 180-day extension until June 24, 2024 to regain $1.00 minimum bid compliance.","Company had been noncompliant since June 29, 2023; initial cure period ended Dec 26, 2023.","To regain compliance, closing bid must be at least $1.00 for 10 consecutive business days.","Company may consider a reverse stock split to cure the deficiency if needed.","No immediate effect on listing or trading; stock continues on Nasdaq under symbol 'SSKN'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256442,"accession_number":"0001140361-23-060180","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences expands distribution agreement with Kosmo Meditech through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Cutech (Kosmo Meditech parent) extended through December 31, 2026 for direct capital and recurring revenue sales in Korea.","Defined annual and quarterly performance-based purchase requirements, with STRATA becoming sole provider of gas and consumables.","CPT codes 96920-96922 revised effective Jan 1, 2024 to 'Excimer laser treatment for psoriasis', impacting Medicare and potentially private insurers.","STRATA's XTRAC and Pharos are the only excimer laser devices currently marketed in the US that meet the revised code description."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256441,"accession_number":"0001140361-23-053319","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q3 revenue down 6% to $8.9M; suspends FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $8.9M vs $9.4M in Q3 2022 (-6.0%); global recurring rev $5.3M vs $5.8M.","Net loss $1.1M ($0.03 loss per share) vs $1.0M loss in Q3 2022.","Non-GAAP EBITDA improved to $1.0M from $0.6M; gross margin fell to 56% from 62%.","Company suspends FY 2023 guidance following management change effective Oct 31, 2023.","Dr. Dolev Rafaeli named CEO and Vice-Chairman, effective October 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":24669000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256440,"accession_number":"0001051514-23-000062","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Strata Skin Sciences promotes Shmuel Gov to Chief Operating Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shmuel Gov promoted to COO effective November 14, 2023.","Previously served as SVP and General Manager at Carlsbad, CA manufacturing and R&D facility.","Joined the company in 2015; over 25 years in medical device manufacturing, logistics, and R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256439,"accession_number":"0001140361-23-050058","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Bob Moccia steps down as CEO; Dolev Rafaeli appointed President & CEO; reverse split approved","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bob Moccia resigned as CEO and board member effective Oct 30, 2023; receives 9 months base salary severance, no 2023 bonus.","Dr. Dolev Rafaeli appointed Vice-Chairman, President, and CEO; 3-year term, base salary $500k, 75% bonus target, option for 1,745,569 shares.","Shareholders approved reverse stock split of common stock at ratio between 1:5 and 1:25, board to set exact ratio within 6 months.","CFO Chris Lesovitz receives $142,500 retention bonus for staying through filing of FY2023 10-K.","All five director nominees elected; advisory votes on executive compensation and frequency (3 years favored) approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273835,"accession_number":"0001140361-23-038802","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q2 revenue $8.3M, net loss $3.1M; FY guidance cut to $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $8.3M vs $9.1M YoY; equipment revenue down to $2.8M from $3.5M due to $1.5M one-time China sale last year.","Net loss $3.1M ($0.09 loss per share) vs $1.9M ($0.05 loss) YoY; adjusted EBITDA loss of $95K vs positive $207K.","FY 2023 guidance revised to $35-38M from prior; cites slowdown in capex and macro factors impacting equipment sales.","Secured up to $12M financing with MidCap Financial; cash balance $10.4M; includes refinancing and $7M new tranche.","73 TheraClear X devices placed; initiated acne clinical study; JCAD publication released."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":15817000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273834,"accession_number":"0001140361-23-034075","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences announces JCAD publication highlighting TheraClearX for acne treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Journal of Clinical and Aesthetic Dermatology published review and expert article on TheraClearX for mild-to-moderate acne vulgaris.","Article highlights visible improvement as early as second treatment, no downtime, and customization for all Fitzpatrick skin types.","CEO Bob Moccia stated the publication expands on device's safety, efficacy, and integration into practice.","Dr. Gilly Munavalli, author, noted TheraClearX is effective non-pharmaceutical acne treatment with little downtime."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273833,"accession_number":"0001140361-23-033456","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Strata Skin Sciences completes $15M debt refinancing with MidCap; adds $7M new tranche, option for $5M more in 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Refinanced existing $8M term loan and drew $7M new tranche on June 30, 2023 from MidCap Financial.","Total debt facility $20M with an additional $5M tranche available upon meeting revenue condition in 2024.","Interest rate: Adjusted Term SOFR plus 7.50% (floor 3.50%); interest-only through June 2026, maturity June 1, 2028.","Amended warrant: 800,000 shares at $0.88 exercise price, exercisable until June 2033; shares to be registered.","Company increased cash to ~$10M, strengthening balance sheet and avoiding near-term equity raise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290917,"accession_number":"0001051514-23-000022","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["3.01","7.01","8.01","9.01","2.02"],"status":"ready","headline":"STRATA Skin Sciences receives NASDAQ bid price deficiency notice; appoints Dr. Uri Geiger as Chairman","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Received NASDAQ notice on June 29, 2023 for bid price below $1.00 for 30 consecutive business days.","Has 180 days (until Dec 26, 2023) to regain compliance by closing at $1.00+ for 10 consecutive trading days.","Dr. Uri Geiger appointed Chairman effective July 3, 2023; William Humphries steps down but remains on Board.","Humphries transition due to becoming CEO of Alcami; Geiger has 20+ years medtech experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290916,"accession_number":"0001140361-23-024714","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q1 revenue up 8.6% to $7.6M; net loss widens to $2.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $7.6M vs $7.0M YoY; global recurring revenue $5.2M, equipment revenue $2.4M.","Net loss of $2.8M ($0.08 loss per share) vs net loss of $2.5M ($0.07 per share) YoY.","Launched TheraClear X in Jan 2023; placed 44 devices in Q1, total 58 U.S. placements.","Sold over 3,000 TheraClear treatments in Q1; signed India distribution deal with Spectra Medical.","Full-year 2023 revenue guidance reaffirmed at $38M–$40M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":7567000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290915,"accession_number":"0001140361-23-017913","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin pre-announces Q1 2023 revenue $7.3-$7.8M, best Q1 since 2016","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2023 revenue $7.3-$7.8 million, strongest first quarter since 2016.","Placed 44 TheraClear X devices in Q1; over 3,000 treatments sold since Jan 2023 launch.","Converted 86 Pharos accounts to XTRAC devices from RaMedical acquisition.","CEO Bob Moccia cites strong sales momentum and expects meaningful revenue impact in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":7567000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311764,"accession_number":"0001140361-23-015159","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences reports record Q4 revenue of $10.6M; FY 2023 guidance $38M-$40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $10.6M (+17% YoY); full-year revenue $36.2M (+21% YoY).","Net loss narrowed to $0.2M in Q4 ($0.005/share) vs $0.8M loss in Q4 2021; full-year net loss $5.5M vs $2.7M.","Domestic installed base of 909 XTRAC devices; acquired TheraClearX acne device in Jan 2022.","FY 2023 revenue guidance of $38M-$40M; entered Mexican market with distribution agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":7567000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311763,"accession_number":"0001051514-23-000013","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STRATA holds no cash deposits or securities with Silicon Valley Bank.","The company has no business relationship of any kind with SVB.","Press release issued March 13, 2023, amid market concerns over SVB's collapse.","No financial impact or counterparty risk to STRATA from SVB failure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311762,"accession_number":"0001051514-23-000011","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 27, 2023 confirming compliance with Rule 5550(a)(2).","Company will continue trading on Nasdaq; delisting risk removed.","CEO Robert Moccia expressed satisfaction with regaining full listing compliance.","No financial impact or other material changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311761,"accession_number":"0001051514-23-000009","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA reports record FY2022 revenue of $35-36M, up 17-19% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited full-year 2022 revenue of $35-36M, vs $30M in 2021.","Revenue at upper end of prior guidance of $33-35M.","Growth driven by XTRAC usage, device redeployment, and international sales.","Full audited results expected in March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":36161000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311760,"accession_number":"0001051514-23-000007","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin posts investor presentation; content unreadable in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Jan 9, 2023 under Item 7.01; presentation furnished as Exhibit 99.1.","Presentation text is corrupted/machine-readable binary; no specific facts extractable.","Investor presentation posted to company website; no financial or operational details discernible.","No material changes or specific guidance identified from available filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-09T23:59:59+00:00|311760"}